40SD02

Drug Profile

40SD02

Latest Information Update: 04 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomedical Frontiers
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 19 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003)have been added to the Haematological disorders therapeutic trials section
  • 28 Mar 2001 Phase-II clinical trials for Iron overload in USA (Injection)
  • 21 Dec 1998 40SD02 has received Orphan Drug Status for Iron overload in the USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top